Prospective multicenter observational study of atezolizumab in patients with unresectable, locally advanced or metastatic non-small cell lung cancer

Prospective multicenter observational study of atezolizumab in patients with unresectable, locally advanced or metastatic non-small cell lung cancer - Prospective multicenter observational study of atezolizumab in lung cancer (J-TAIL)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033133

Enrollment

1000

Registered

2018-06-25

Start date

2018-08-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients 20 years of age or older at the time of signed consent. (2)Patients with locally advanced or metastatic non-small cell lung cancer. (3)Patients who are scheduled to start atezolizumab monotherapy, based on the atezolizumab package insert and the Optimal Use Promotion Guideline. (4)Patients who signed informed consent form before enrolling the study. The consent from a legally acceptable representative is required for the patients with uncertain capacity of judgments.

Exclusion criteria

Exclusion criteria: (1)Patients who are considered to be unsuitable for enrolment into the study by the investigator's judgment.

Design outcomes

Primary

Measure	Time frame
18 month-survival rate	—

Countries

Japan

Contacts

Public ContactNaoyuki Omura

Mebix, Inc. Clinical Research Operation

j-tail@mebix.co.jp03-4362-4504

Outcome results